Low levels of nitric oxide and carbon monoxide in α1-antitrypsin deficiency

2002 ◽  
Vol 93 (6) ◽  
pp. 2038-2043 ◽  
Author(s):  
Roberto F. Machado ◽  
James K. Stoller ◽  
Daniel Laskowski ◽  
Shuo Zheng ◽  
Joseph A. Lupica ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Carbon Monoxide ◽  
Chronic Obstructive ◽  
Exhaled Breath ◽  
Healthy Controls ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Antitrypsin Deficiency ◽  
At Deficiency ◽  
Noninvasive Markers

Quantitations of exhaled nitric oxide (NO) and carbon monoxide (CO) have been proposed as noninvasive markers of airway inflammation. We hypothesized that exhaled CO is increased in individuals with α1-antitrypsin (AT) deficiency, who have lung inflammation and injury related to oxidative and proteolytic processes. Nineteen individuals with α1-AT deficiency, 22 healthy controls, and 12 patients with non-α1-AT-deficient chronic obstructive pulmonary disease (COPD) had NO, CO, CO2, and O2 measured in exhaled breath. Individuals with α1-AT deficiency had lower levels of NO and CO than control or COPD individuals. α1-AT-deficient and COPD patients had lower exhaled CO2 than controls, although only α1-AT-deficient patients had higher exhaled O2 than healthy controls. NO was correlated inversely with exhaled O2 and directly with exhaled CO2, supporting a role for NO in regulation of gas exchange. Exhaled gases were not significantly related to corticosteroid use or lung function. Demonstration of lower than normal CO and NO levels may be useful as an additional noninvasive method to evaluate α1-AT deficiency in individuals with a severe, early onset of obstructive lung disease.

scholarly journals Expired air nitric oxide in patients with bronchial asthma and chronic obstructive pulmonary disease with different disease course

2013 ◽  
Vol 10 (2) ◽  
pp. 12-18
Author(s):  
G B Fedoseev ◽  
V I Trofimov ◽  
V G Timchik ◽  
K V Negrutsa ◽  
T S Razumovskaya ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Bronchial Asthma ◽  
Chronic Obstructive ◽  
Healthy Controls ◽  
Disease Course ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Severity Of The Disease ◽  
Airways Inflammation ◽  
Expired Air

Expired air nitric oxide was measured in 113 subjects (26 healthy controls, 64 bronchial asthma (BA) patients and 23 COPD patients. In BA patients 10 had mild course of the disease. In 50 the course was estimated as moderate, 4 patients had severe course of the disease. In 20 patients BA was associated with COPD. The results revealed the dependence of FeNO on following factors: severity of the disease: in severe and moderate BA course FeNO was significantly higher than in mild BA; on phase of the disease: in exacerbation FeNO was significantly higher than in remission; on control of the disease: in patients, in whom it was difficult to reach the disease control, FeNO was higher than in others. In COPD patients FeNO was significantly lower than in BA ones. Even in subjects with marked airways inflammation manifested by high sputum cellularity FeNO was low.

scholarly journals Neuromorphic on-chip recognition of saliva samples of COPD and healthy controls using memristive devices

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Pouya Soltani Zarrin ◽  
Finn Zahari ◽  
Mamathamba K. Mahadevaiah ◽  
Eduardo Perez ◽  
Hermann Kohlstedt ◽  
...  
Keyword(s):  
Medical Devices ◽  
Energy Efficient ◽  
Performance Evaluations ◽  
Chronic Obstructive ◽  
Healthy Controls ◽  
Effective Management ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Life Threatening ◽  
On Chip

AbstractChronic Obstructive Pulmonary Disease (COPD) is a life-threatening lung disease, affecting millions of people worldwide. Implementation of Machine Learning (ML) techniques is crucial for the effective management of COPD in home-care environments. However, shortcomings of cloud-based ML tools in terms of data safety and energy efficiency limit their integration with low-power medical devices. To address this, energy efficient neuromorphic platforms can be used for the hardware-based implementation of ML methods. Therefore, a memristive neuromorphic platform is presented in this paper for the on-chip recognition of saliva samples of COPD patients and healthy controls. Results of its performance evaluations showed that the digital neuromorphic chip is capable of recognizing unseen COPD samples with accuracy and sensitivity values of 89% and 86%, respectively. Integration of this technology into personalized healthcare devices will enable the better management of chronic diseases such as COPD.

scholarly journals Relationship of the Content of Systemic and Endobronchial Soluble Molecules of CD25, CD38, CD8, and HLA-I-CD8 and Lung Function Parameters in COPD Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Nailya Kubysheva ◽  
Larisa Postnikova ◽  
Svetlana Soodaeva ◽  
Viкtor Novikov ◽  
Tatyana Eliseeva ◽  
...  
Keyword(s):  
Lung Function ◽  
Blood Serum ◽  
Exhaled Breath Condensate ◽  
Diagnostic Methods ◽  
Stable Phase ◽  
Chronic Obstructive ◽  
Exhaled Breath ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Severe Copd

The definition of new markers of local and systemic inflammation of chronic obstructive pulmonary disease (COPD) is one of the priority directions in the study of pathogenesis and diagnostic methods improvement for this disease. We investigated 91 patients with COPD and 21 healthy nonsmokers. The levels of soluble CD25, CD38, CD8, and HLA-I-CD8 molecules in the blood serum and exhaled breath condensate (EBC) in moderate-to-severe COPD patients during exacerbation and stable phase were studied. An unidirectional change in the content of sCD25, sCD38, and sCD8 molecules with increasing severity of COPD was detected. The correlations between the parameters of lung function and sCD8, sCD25, and sHLA-I-CD8 levels in the blood serum and EBC were discovered in patients with severe COPD. The findings suggest a pathogenetic role of the investigated soluble molecules of the COPD development and allow considering the content of sCD8, sCD25, and sHLA-I-CD8 molecules as additional novel systemic and endobronchial markers of the progression of chronic inflammation of this disease.

scholarly journals Chronic Obstructive Pulmonary Disease Patients Have Increased Levels of Plasma Inflammatory Mediators Reported Upregulated in Severe COVID-19

2021 ◽  
Vol 12 ◽  
Author(s):  
Nathalie Acevedo ◽  
Jose Miguel Escamilla-Gil ◽  
Héctor Espinoza ◽  
Ronald Regino ◽  
Jonathan Ramírez ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Plasma Proteins ◽  
Viral Infections ◽  
Chronic Obstructive ◽  
Healthy Controls ◽  
Obstructive Pulmonary Disease ◽  
Asthmatic Patients ◽  
Copd Patients ◽  
Increased Risk

BackgroundChronic obstructive pulmonary disease (COPD) is associated with increased risk of severe COVID-19, but the mechanisms are unclear. Besides, patients with severe COVID-19 have been reported to have increased levels of several immune mediators.MethodsNinety-two proteins were quantified in 315 plasma samples from 118 asthmatics, 99 COPD patients and 98 healthy controls (age 40-90 years), who were recruited in Colombia before the COVID-19 pandemic. Protein levels were compared between each disease group and healthy controls. Significant proteins were compared to the gene signatures of SARS-CoV-2 infection reported in the “COVID-19 Drug and Gene Set Library” and with experimentally tested protein biomarkers of severe COVID-19.ResultsForty-one plasma proteins showed differences between patients and controls. Asthmatic patients have increased levels in IL-6 while COPD patients have a broader systemic inflammatory dysregulation driven by HGF, OPG, and several chemokines (CXCL9, CXCL10, CXCL11, CX3CL1, CXCL1, MCP-3, MCP-4, CCL3, CCL4 and CCL11). These proteins are involved in chemokine signaling pathways related with response to viral infections and some, were found up-regulated upon SARS-CoV-2 experimental infection of Calu-3 cells as reported in the COVID-19 Related Gene Sets database. An increase of HPG, CXCL9, CXCL10, IL-6, MCP-3, TNF and EN-RAGE has also been experimentally detected in patients with severe COVID-19.ConclusionsCOPD patients have altered levels of plasma proteins that have been reported increased in patients with severe COVID-19. Our study suggests that COPD patients have a systemic dysregulation in chemokine networks (including HGF and CXCL9) that could make them more susceptible to severe COVID-19. Also, that IL-6 levels are increased in some asthmatic patients (especially in females) and this may influence their response to COVID-19. The findings in this study depict a novel panel of inflammatory plasma proteins in COPD patients that may potentially associate with increased susceptibility to severe COVID-19 and might be useful as a biomarker signature after future experimental validation.

scholarly journals Diffusing capacity in chronic obstructive pulmonary disease assessment: A meta-analysis

2021 ◽  
Vol 18 ◽  
pp. 147997312110563
Author(s):  
Yingmeng Ni ◽  
Youchao Yu ◽  
Ranran Dai ◽  
Guochao Shi
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Carbon Monoxide ◽  
Pulmonary Hypertension ◽  
Pulmonary Disease ◽  
Meta Analysis ◽  
Chronic Obstructive ◽  
Diffusing Capacity ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Exacerbation Risk

To achieve a multidimensional evaluation of chronic obstructive pulmonary disease (COPD) patients, the spirometry measures are supplemented by assessment of symptoms, risk of exacerbations, and CT imaging. However, the measurement of diffusing capacity of the lung for carbon monoxide (DLCO) is not included in most common used models of COPD assessment. Here, we conducted a meta-analysis to evaluate the role of DLCO in COPD assessment. The studies were identified by searching the terms “diffusing capacity” OR “diffusing capacity for carbon monoxide” or “DLCO” AND “COPD” AND “assessment” in Pubmed, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Scopus, and Web of Science databases. The mean difference of DLCO % predict was assessed in COPD patient with different severity (according to GOLD stage and GOLD group), between COPD patients with or without with frequent exacerbation, between survivors and non-survivors, between emphysema dominant and non-emphysema dominant COPD patients, and between COPD patients with or without pulmonary hypertension. 43 studies were included in the meta-analysis. DLCO % predicted was significantly lower in COPD patients with more severe airflow limitation (stage II/IV), more symptoms (group B/D), and high exacerbation risk (group C/D). Lower DLCO % predicted was also found in exacerbation patients and non-survivors. Low DLCO % predicted was related to emphysema dominant phenotype, and COPD patients with PH. The current meta-analysis suggested that DLCO % predicted might be an important measurement for COPD patients in terms of severity, exacerbation risk, mortality, emphysema domination, and presence of pulmonary hypertension. As diffusion capacity reflects pulmonary ventilation and perfusion at the same time, the predictive value of DLCO or DLCO combined with other criteria worth further exploration.

scholarly journals Exhaled Nitric Oxide as a Biomarker in COPD and Related Comorbidities

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Mario Malerba ◽  
Alessandro Radaeli ◽  
Alessia Olivini ◽  
Giovanni Damiani ◽  
Beatrice Ragnoli ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Inflammatory Diseases ◽  
Exhaled Nitric Oxide ◽  
Airflow Limitation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Increased Risk ◽  
Antitrypsin Deficiency ◽  
Alpha 1 Antitrypsin Deficiency ◽  
Alpha 1 Antitrypsin

Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease characterized by persistent, progressive airflow limitation. Recent studies have underlined that COPD is correlated to many systemic manifestations, probably due to an underlying pattern of systemic inflammation. In COPD fractional exhaled Nitric Oxide (FeNO) levels are related to smoking habits and disease severity, showing a positive relationship with respiratory functional parameters. Moreover FeNO is increased in patients with COPD exacerbation, compared with stable ones. In alpha-1 antitrypsin deficiency, a possible cause of COPD, FeNO levels may be monitored to early detect a disease progression. FeNO measurements may be useful in clinical setting to identify the level of airway inflammation,per seand in relation to comorbidities, such as pulmonary arterial hypertension and cardiovascular diseases, either in basal conditions or during treatment. Finally, some systemic inflammatory diseases, such as psoriasis, have been associated with higher FeNO levels and potentially with an increased risk of developing COPD. In these systemic inflammatory diseases, FeNO monitoring may be a useful biomarker for early diagnosis of COPD development.

Sign in / Sign up

Export Citation Format

Share Document